ArticleJCEM case reports2026
Ultra-rapid prolactin normalization with cabergoline in a premenopausal woman with epilepsy and giant prolactinoma.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant prolactinomas are rare pituitary tumors characterized by extremely high prolactin levels and extensive extrasellar invasion. While dopamine agonists are usually effective, they may require months to normalize prolactin. We report a 47-year-old premenopausal woman presenting with new-onset temporal epilepsy and secondary amenorrhea. Assessments revealed marked hyperprolactinemia (mean serum prolactin concentration, 3902 ng/mL [SI: 169.8 nmol/L]) (reference range, 5.0-30.0 ng/mL [SI: 0.22-1.30 nmol/L]), and an invasive 47 × 43 × 50 mm adenoma extending into the right temporal lobe. After initiating cabergoline (0.25 mg/day), serum prolactin dropped to 802 ng/mL (SI: 34.9 nmol/L) within 18 hours and normalized by day 4 (12.7 ng/mL [SI: 0.55 nmol/L]). Polyethylene glycol recovery excluded macroprolactinemia. Despite ultra-rapid biochemical remission, magnetic resonance imaging at 3 and 6 months revealed no tumor shrinkage despite increasing cabergoline to a maximal tolerated dose of 0.75 mg/week. The patient remained seizure free and resumed normal menses. This case illustrates a striking dissociation between hormonal sensitivity and a lack of radiological regression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.